The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Open accessAbstract
Most normal mammalian cells have a finite lifespan, thought to constitute a protective mechanism against unlimited proliferation. This phenomenon, called senescence, is driven by telomere attrition, which triggers the induction of tumour suppressors including p16(INK4a) (ref. 5). In cultured cells, senescence can be elicited prematurely by oncogenes; however, whether such oncogene-induced senescence represents a physiological process has long been debated. Human naevi (moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations (predominantly V600E, where valine is substituted for glutamic acid) in BRAF, a protein kinase and downstream effector of Ras. Nonetheless, naevi typically remain in a growth-arrested state for decades and only rarely progress into malignancy (melanoma). This raises the question of whether naevi undergo BRAF(V600E)-induced senescence. Here we show that sustained BRAF(V600E) expression in human melanocytes induces cell cycle arrest, which is accompanied by the induction of both p16(INK4a) and senescence-associated acidic beta-galactosidase (SA-beta-Gal) activity, a commonly used senescence marker. Validating these results in vivo, congenital naevi are invariably positive for SA-beta-Gal, demonstrating the presence of this classical senescence-associated marker in a largely growth-arrested, neoplastic human lesion. In growth-arrested melanocytes, both in vitro and in situ, we observed a marked mosaic induction of p16(INK4a), suggesting that factors other than p16(INK4a) contribute to protection against BRAF(V600E)-driven proliferation. Naevi do not appear to suffer from telomere attrition, arguing in favour of an active oncogene-driven senescence process, rather than a loss of replicative potential. Thus, both in vitro and in vivo, BRAF(V600E)-expressing melanocytes display classical hallmarks of senescence, suggesting that oncogene-induced senescence represents a genuine protective physiological process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
From Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2008) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [225]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mouse models of melanoma and human nevi (both oncogene driven) show accumulation of SA-β-gal+–CDKN2A+ foci224,225.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [225]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, developmental senescent cells express p21WAF1/Cip1 but not p16INK4a9,10, while the reverse is observed in melanocytic nevi36,37.”
From Algorithmic assessment of cellular senescence in experimental and clinical specimens (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This type of oncogene-induced senescence (OIS) is frequently observed in premalignant and benign tumour tissues [37 -39] but not in advanced malignant tumours, where cancer cells have already bypassed senescence.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [37]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Hallmarks of senescent cells were subsequently identified in dermal premalignant lesions, specifically human melanocytic naevi 81,82 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Studies in various mouse models, supported by correlative evidence from human- derived tissue samples, have underscored the tumour- suppressive role of OIS 81,120-123 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [81]
In the citing paper
“Oncogene-induced senescence protects against tumor initiation 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [35]
In the citing paper
“OIS is a powerful tumor suppressor mechanism 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [35]
In the citing paper
“in vitro experiments showed that cells that lack functional p53 or overexpress the H3K9me3 demethylase JMJD2c46,50 — which therefore cannot enter senescence in response to pro-senescent oncogenes such as Ras-G12V or Braf-V600E46,51 — also failed to enter VIS and lacked a SASP upon infection with SARS-CoV-2 (ref.28).”
From COVID-19 and cellular senescence (2023) · cites this paper as [51]
In the citing paper
“Studies have demonstrated high levels of senescence in premalignant lesions and lower levels in invasive disease, suggesting a role for senescence in blocking malignant progression [2,31,32].”
From Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies (2020) · cites this paper as [32]
In the citing paper
“human melanocytic naevi (an OIS model), remain non-proliferative for decades without transformation into malignant melanoma 25”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [25]
In the citing paper
“This is a seminal study that identified OIS of human melanocytic naevi.”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [25]
In the citing paper
“Senescence markers are detected in premalignant tumor lesions but not at later stages of tumor development [17,18,19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Benign melanocytic lesions, which are melanoma precursors in humans, express high p16 and are an in vivo example of OIS [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Indeed, such telomeres are not visibly shorter than functional telomeres [114] in human melanocytic nevi with frequent BRAF mutations, a typical OIS feature in vivo [19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Indeed, its locus is more commonly deleted or silenced than mutated in melanoma, the more malignant later stage of disease [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“For example, N-RAS- or B-RAF-activating mutations are commonly found in benign melanocytic nevi that show features of senescence, such as elevated p16 levels, but that do not express appreciable levels of ARF or p53 [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“In humans, Ras activation appears to induce only p16 [19,127].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“senescence occurs during the formation of benign cutaneous melanocytic nevi that express an oncogenic form of BRAF [19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Importantly, this work also provided evidence for the occurrence of 4N senescent cells in human melanocyte naevi, the first in vivo senescence model, 94 suggesting that the G2 exit program has a more general role in senescence.”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [94]
In the citing paper
“The acronym oncogene-induced senescence (OIS) was coined following the demonstration that the aberrant activation of oncogenes (e.g., Ras, BRAF V600E, and c-Myc) or loss of tumor suppressor genes (e.g., PTEN) temporarily arrests a large variety of tumors in a pre-malignant state 180-183 (Figure 3B).”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [182]
In the citing paper
“BRAFV600E mutation alone is often insufficient to drive malignant transformation of melanocytes24.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Reversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
Lowe, S. W., Cepero, E., & Evan, G. I. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,374
Research works printed but not linked: 1
- Peeper, D. S. & Mooi, W. J. Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathology 41, S139–S143 (2002)
Cited by
Sorted by citations
Items 501–600 of 1,009
Alterations of the pigmentation system in the aging process
Kang, H. Y., Lee, J. W., Papaccio, F., Bellei, B., & Picardo, M. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12994 · Cited by 97
Wu, X. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl208 · Cited by 97
Control of cellular senescence by CPEBPreprint
Groisman, I., Ivshina, M., Marin, V., Kennedy, N. J., Davis, R. J., & Richter, J. D. (2006) · Genes & Development · doi:10.1101/gad.1438906 · Cited by 97
Genetics of melanoma progression: the rise and fall of cell senescence
Bennett, D. C. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12422 · Cited by 96
Cellular senescence and chromatin organisation
Narita, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603636 · Cited by 96
Transcriptional regulation of cellular senescence
Lanigan, F., Geraghty, J. G., & Bracken, A. P. (2011) · Oncogene · doi:10.1038/onc.2011.34 · Cited by 95
CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma
McNeal, A. S., Liu, K., Nakhate, V., Natale, C. A., Duperret, E. K., Capell, B. C., Dentchev, T., Berger, S. L., Herlyn, M., Seykora, J. T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0196 · Cited by 95
Inflammation and melanoma metastasis
Melnikova, V. O., & Bar‐Eli, M. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00570.x · Cited by 95
de Keizer, P. L. J., Packer, L. M., Szypowska, A. A., Riedl-Polderman, P. E., van den Broek, N. J. F., de Bruin, A., Dansen, T. B., Marais, R., Brenkman, A. B., & Burgering, B. M. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1563 · Cited by 94
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
The role of senescence in cancer development
Mavrogonatou, E., Pratsinis, H., & Kletsas, D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.018 · Cited by 95
The evolution and ecology of benign tumors
Boutry, J., Tissot, S., Újvári, B., Capp, J., Giraudeau, M., Nedelcu, A. M., & Frédéric Thomas, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188643 · Cited by 94
Zampetidis, C., Galanos, P., Angelopoulou, A., Zhu, Y., Polyzou, A., Karamitros, T., Kotsinas, A., Lаgopati, N., Mourkioti, I., Mirzazadeh, R., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.10.017 · Cited by 94
Hafner, C. M., Toll, A., Fernández-Casado, A., Earl, J., Marqués, M., Acquadro, F., Méndez‐Pertuz, M., Urioste, M., Malats, N., Burns, J. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008365107 · Cited by 94
Role of BRAF‐V600E in the serrated pathway of colorectal tumourigenesis
Minoo, P., Moyer, M. P., & Jass, J. R. (2007) · The Journal of Pathology · doi:10.1002/path.2160 · Cited by 94
Meleti, M., Mooi, W. J., Casparie, M. K., & van der Waal, I. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2006.11.013 · Cited by 94
Self-citationPremature cell senescence in human skin: Dual face in chronic acquired pigmentary disorders
Bellei, B., & Picardo, M. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100981 · Cited by 93
Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
Wu, P., Becker, A., & Park, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155436 · Cited by 93
Tu, Z., Aird, K. M., Bitler, B. G., Nicodemus, J. P., Beeharry, N., Xia, B., Yen, T. J., & Zhang, R. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.10.010 · Cited by 94
The Senescence–Stemness Alliance – A Cancer-Hijacked Regeneration Principle
Milanovic, M., Yu, Y., & Schmitt, C. A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.09.001 · Cited by 92
Noncoding RNA control of cellular senescence
Abdelmohsen, K., & Gorospe, M. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1297 · Cited by 92
Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer
Choi, Y. W., Kim, Y. H., Oh, S. Y., Suh, K. W., Kim, Y., Lee, G., Yoon, J. E., Park, S. S., Lee, Y., Park, Y. J., et al. (2021) · Advanced Science · doi:10.1002/advs.202002497 · Cited by 92
Cellular Senescence in the Development and Treatment of Cancer
Saretzki, G. C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210789941874 · Cited by 92
Petti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., & Sensi, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4671 · Cited by 92
Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer
Mitri, D. D., & Alimonti, A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.005 · Cited by 92
Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress
Croft, A. J., Tay, K. H., Boyd, S. C., Guo, S., Jiang, C. C., Lai, F., Tseng, H., Jin, L., Rizos, H., Hersey, P., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.325 · Cited by 91
Schartl, M., Wilde, B., Laisney, J. A. G. C., Taniguchi, Y., Takeda, S., & Meierjohann, S. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.213 · Cited by 91
Could BRAF Mutations in Melanocytic Lesions Arise from DNA Damage Induced by Ultraviolet Radiation?
Thomas, N. E., Berwick, M., & Cordeiro‐Stone, M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700458 · Cited by 91
Webster, M. R., Xu, M., Kinzler, K. A., Kaur, A., Appleton, J., O’Connell, M. P., Marchbank, K., Valiga, A. A., Dang, V. M., Perego, M., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12330 · Cited by 91
Senescence-Associated MicroRNAs
Munk, R. B., Panda, A. C., Grammatikakis, I., Gorospe, M., & Abdelmohsen, K. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.008 · Cited by 90
Comparative analysis of volatile metabolomics signals from melanoma and benign skin: a pilot study
Abaffy, T., Moller, M. G., Riemer, D. D., Milikowski, C., & DeFazio, R. A. (2013) · Metabolomics · doi:10.1007/s11306-013-0523-z · Cited by 90
Salgado, C. M., Basu, D., Nikiforova, M. N., Bauer, B. S., Johnson, D., Rundell, V. L. M., Grunwaldt, L. J., & Reyes‐Múgica, M. (2014) · Pediatric and Developmental Pathology · doi:10.2350/14-10-1566-oa.1 · Cited by 90
Senescence induction; a possible cancer therapy
LLeonart, M. E., Artero‐Castro, A., & Kondoh, H. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-3 · Cited by 90
Michailidou, C., Jones, M., Walker, P., Kamarashev, J. A., Kelly, A., & Hurlstone, A. F. L. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001149 · Cited by 90
Massive reshaping of genome-nuclear lamina interactions during oncogene-induced senescence.
Lenain, C., de Graaf, C. A., Pagie, L., Visser, N. L., de Haas, M., de Vries, S. S., Peric-Hupkes, D., van Steensel, B., & Peeper, D. S. (2017) · Genome Research · doi:10.1101/gr.225763.117 · Cited by 89
Self-citationDikovskaya, D., Cole, J. J., Mason, S. M., Nixon, C., Karim, S. A., McGarry, L., Clark, W., Hewitt, R. N., Sammons, M. A., Zhu, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.055 · Cited by 89
Abaffy, T., DUNCAN, R. C., Riemer, D. D., Tietje, O., Elgart, G. W., Milikowski, C., & DeFazio, R. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013813 · Cited by 89
Wagner, J. L., Damaschke, N., Yang, B., Truong, M., Guenther, C. M., McCormick, J. R., Huang, W., & Jarrard, D. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124366 · Cited by 89
Senescence and immortality in hepatocellular carcinoma
Öztürk, M., Arslan-Ergül, A., Baǧışlar, S., Şentürk, Ş., & Yuzugullu, H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.048 · Cited by 89
Epidemiologic evidence for a role of telomere dysfunction in cancer etiology
Prescott, J., Wentzensen, I. M., Savage, S. A., & Vivo, I. D. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.06.009 · Cited by 88
Genetic and epigenetic dependencies in colorectal cancer development
Parmar, S., & Easwaran, H. (2022) · Gastroenterology report · doi:10.1093/gastro/goac035 · Cited by 89
Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence
Leikam, C., Hufnagel, A., Schartl, M., & Meierjohann, S. (2008) · Oncogene · doi:10.1038/onc.2008.323 · Cited by 88
Tsai, J., Liau, J., Lin, Y., Lin, L., Cheng, Y., Cheng, M.-L., & Jeng, Y. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.35 · Cited by 88
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming
Torrano, J., Emran, A. A., Hammerlindl, H., & Schaider, H. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0644-y · Cited by 87
Dormant cancer cells: programmed quiescence, senescence, or both?
Truskowski, K., Amend, S. R., & Pienta, K. J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10073-z · Cited by 87
p16INK4a as a Second Effector of the Telomere Damage Pathway
Jacobs, J. J. L., & de Lange, T. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2104 · Cited by 87
Hogstad, B., Berres, M., Chakraborty, R., Tang, J., Bigenwald, C., Serasinghe, M. N., Lim, K. P. H., Lin, H., Man, T., Remark, R., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161881 · Cited by 86
Mazzoni, M., Mauro, G., Erreni, M., Romeo, P., Minna, E., Vizioli, M. G., Belgiovine, C., Rizzetti, M. G., Pagliardini, S., Avigni, R., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1198-8 · Cited by 86
Liu, B., Peng, Z., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Huang, S., Luo, P., & Cheng, Q. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02284-z · Cited by 86
Bandyopadhyay, D., Curry, J. L., Lin, Q., Richards, H. W., Chen, D., Hornsby, P. J., Timchenko, N. A., & Medrano, E. E. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00308.x · Cited by 86
ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome
Tavares, C., Melo, M., Cameselle‐Teijeiro, J., Soares, P., & Sobrinho-Simões, M. A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0605 · Cited by 86
Consequences of mitotic slippage for antimicrotubule drug therapy
Cheng, B., & Crasta, K. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0147 · Cited by 86
Antiprotease therapy in cancer: hot or not?
Lah, T. T., Alonso, M. B. D., & Noorden, C. J. F. V. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.257 · Cited by 86
Clonal Architectures and Driver Mutations in Metastatic Melanomas
Ding, L., Kim, M., Kanchi, K., Dees, N. D., Lu, C., Griffith, M., Fenstermacher, D., Sung, H., Miller, C. A., Goetz, B. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111153 · Cited by 85
Molecular Genomic Profiling of Melanocytic Nevi
Colebatch, A. J., Ferguson, P. M., Newell, F., Kazakoff, S. H., Witkowski, T., Dobrovic, A., Johansson, P. A., Saw, R. P. M., Stretch, J. R., McArthur, G. A., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.033 · Cited by 85
p38α and p38γ Mediate Oncogenic ras-induced Senescence through Differential Mechanisms
Kwong, J., Hong, L., Liao, R., Deng, Q., Han, J., & Sun, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808327200 · Cited by 85
Exploiting tumor cell senescence in anticancer therapy
Lee, M., & Lee, J. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.2.005 · Cited by 85
Yu, H., McDaid, R., Lee, J., Possik, P. A., Li, L., Kumar, S. M., Elder, D. E., Belle, P. A. V., Gimotty, P. A., Guerra, M., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081057 · Cited by 85
NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
Tschandl, P., Berghoff, A. S., Preusser, M., Burgstaller-Muehlbacher, S., Pehamberger, H., Okamoto, I., & Kittler, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069639 · Cited by 85
Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma
Wang, J. X., Fukunaga‐Kalabis, M., & Herlyn, M. (2016) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0349-3 · Cited by 85
Faheem, M. M., Seligson, N. D., Ahmad, S. M., Rasool, R. U., Gandhi, S. G., Bhagat, M., & Goswami, A. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0286-z · Cited by 84
Erdheim–Chester disease: a rapidly evolving disease model
Pegoraro, F., Papo, M., Maniscalco, V., Charlotte, F., Haroche, J., & Vaglio, A. (2020) · Leukemia · doi:10.1038/s41375-020-0944-4 · Cited by 84
Giroud, J., Bouriez, I., Paulus, H., Pourtier, A., Debacq‐Chainiaux, F., & Pluquet, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310788 · Cited by 87
Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?
Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2038 · Cited by 84
Camps, J., Grade, M., Nguyen, Q. T., Hörmann, P., Becker, S., Hummon, A. B., Rodriguez, V., Chandrasekharappa, S. C., Chen, Y., Difilippantonio, M. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2864 · Cited by 84
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 86
BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology
Bigenwald, C., Le Berichel, J., Wilk, C. M., Chakraborty, R., Chen, S. T., Tabachnikova, A., Mancusi, R., Abhyankar, H., Casanova-Acebes, M., Laface, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01304-x · Cited by 83
Consequences of Lamin B1 and Lamin B Receptor Downregulation in Senescence
Lukášová, E., Kovařík, A., & Kozubek, S. (2018) · Cells · doi:10.3390/cells7020011 · Cited by 83
Noncatalytic Function of ERK1/2 Can Promote Raf/MEK/ERK-mediated Growth Arrest Signaling
Hong, S., Yoon, S., Moelling, C., Arthan, D., & Park, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012591 · Cited by 83
Cellular senescence: a hitchhiker’s guide
Aravinthan, A. D. (2015) · Human Cell · doi:10.1007/s13577-015-0110-x · Cited by 83
Sorafenib-Induced Eruptive Melanocytic Lesions
Kong, H. H., Sibaud, V., Turner, M. L. C., Fojo, T., Hornyak, T. J., & Chevreau, C. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.6.820 · Cited by 83
Barreto-Andrade, J. C., Efimova, E. V., Mauceri, H. J., Beckett, M. A., Sutton, H. G., Darga, T. E., Vokes, E. E., Posner, M. C., Kron, S. J., & Weichselbaum, R. R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0061 · Cited by 83
Huillard, E., Hashizume, R., Phillips, J. J., Griveau, A., Ihrie, R. A., Aoki, Y., Nicolaides, T. P., Perry, A., Waldman, T. A., McMahon, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117255109 · Cited by 83
PBISe, a novel selenium-containing drug for the treatment of malignant melanoma
Madhunapantula, S. V., Desai, D. H., Sharma, A. K., Huh, S. J., Amin, S., & Robertson, G. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2267 · Cited by 83
BRAF,NRASandHRASmutations in spitzoid tumours and their possible pathogenetic significance
Forno, P. D., Pringle, J. H., Fletcher, A. A., Bamford, M. W., Su, L. D., Potter, L., & Saldanha, G. S. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09181.x · Cited by 83
Is cellular senescence an example of antagonistic pleiotropy?
Giaimo, S., & di Fagagna, F. D. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00807.x · Cited by 84
Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis
Blander, H. D., Morel, A., Senaratne, A. P., Ouzounova, M., & Puisieux, A. (2021) · Cancers · doi:10.3390/cancers13184561 · Cited by 82
Therapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 82
Bailet, O., Fenouille, N., Abbe, P., Robert, G., Rocchi, S., Gonthier, N., Denoyelle, C., Ticchioni, M., Ortonne, J. P., Ballotti, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2690 · Cited by 82
Self-citationSenescence As an Anticancer Mechanism
Hornsby, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3101 · Cited by 82
Therapeutic strategies for inhibiting oncogenic BRAF signaling
Halilovic, E., & Solit, D. B. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.014 · Cited by 82
Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
Haferkamp, S., Scurr, L. L., Becker, T. M., Frausto, M., Kefford, R. F., & Rizos, H. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.5 · Cited by 81
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
Maddodi, N., Huang, W., Havighurst, T., Kim, K., Jack Longley, B., & Setaluri, V. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.26 · Cited by 80
A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity
Conde‐Perez, A., Gros, G., Longvert, C., Pedersen, M., Petit, V., Aktary, Z., Virós, A., Gesbert, F., Delmas, V., Rambow, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms9093 · Cited by 80
Targeting Mutant BRAF in Melanoma
Kudchadkar, R. R., Paraiso, K. H. T., & Smalley, K. S. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824b436e · Cited by 80
Caveolin-1, a master regulator of cellular senescence
Volonté, D., & Galbiati, F. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09875-w · Cited by 79
Cell senescence in neuropathology: A focus on neurodegeneration and tumours
Carreno, G., Guiho, R., & Martínez-Barberá, J. P. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12689 · Cited by 83
Lessons from senescence: Chromatin maintenance in non-proliferating cells
Singh, T., & Adams, P. D. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.07.014 · Cited by 80
Corpet, A., Olbrich, T., Gwerder, M., Fink, D., & Stucki, M. (2013) · Cell Cycle · doi:10.4161/cc.26988 · Cited by 80
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis
Hölzel, M., & Tüting, T. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.009 · Cited by 80
Breaking news: high-speed race ends in arrest – how oncogenes induce senescence
Micco, R. D., Fumagalli, M., & di Fagagna, F. D. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.012 · Cited by 80
Nakamura, M., Ohsawa, S., & Igaki, T. (2014) · Nature Communications · doi:10.1038/ncomms6264 · Cited by 79
Sang, B., Zhang, Y. Y., Guo, S., Kong, L. F., Cheng, Q., Liu, G., Thorne, R. F., Zhang, X. D., Jin, L., & Wu, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805950115 · Cited by 79
Unexpected Pieces to the Senescence Puzzle
Cichowski, K. M., & Hahn, W. C. (2008) · Cell · doi:10.1016/j.cell.2008.05.027 · Cited by 79
Mančíková, V., Buj, R., Castelblanco, E., Inglada‐Pérez, L., Diez, A., de Cubas, A. A., Currás-Freixes, M., Maravall, F. X., Mauricio, D., Matías‐Guiu, X., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28703 · Cited by 78
Noppe, G., Dekker, P., Koning‐Treurniet, C. D., Blom, J., van Heemst, D., Dirks, R. W., Tanke, H. J., Westendorp, R. G. J., & Maier, A. B. (2009) · Cytometry Part A · doi:10.1002/cyto.a.20796 · Cited by 78
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells
Neault, M., Mallette, F. A., & Richard, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.068 · Cited by 78
Xu, M., Yu, Q., Subrahmanyam, R., Difilippantonio, M. J., Ried, T., & Sen, J. M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01360-07 · Cited by 78
Cellular senescence mediated by p16INK4A-coupled miRNA pathways
Overhoff, M. G., Garbe, J. C., Koh, J., Stampfer, M. R., Beach, D. H., & Bishop, C. L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1096 · Cited by 77
Metadata
- Authors
- Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Michigan (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Mooi, Wolter J.
- Peeper, Daniel S.
- Venue
- Nature
- Published
- 2005-08
- Volume
- 436
- Issue
- 7051
- Pages
- 720-724
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2150740687
- Semantic Scholar
- bfbf433cb25b4a5e054e35a6850376801a03b87d
- Cited by
- 2,160
- References
- 31
- Citations by year
- 2026: 35 · 2025: 43 · 2024: 70 · 2023: 82 · 2022: 77 · 2021: 85 · 2020: 86 · 2019: 108 · 2018: 99 · 2017: 91 · 2016: 121 · 2015: 112 · 2014: 120 · 2013: 143 · 2012: 136
- FWCI
- 66.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- cellular senescence, BRAF V600E mutation, melanocytes, nevi, melanoma, cell cycle arrest, senescence-associated heterochromatin foci, SUV39H1, histone methyltransferase, p16INK4a, p53, PTEN, oncogene-induced senescence, tumor suppression
- MeSH terms
- beta-Galactosidase, Cell Cycle, Cell Line, Fibroblasts, Humans, Infant, Melanocytes, Nevus, Telomere, Cellular Senescence, In Situ Hybridization, Fluorescence, Cyclin-Dependent Kinase Inhibitor p16, Proto-Oncogene Proteins B-raf, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
